Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) EPS (Basic) (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed EPS (Basic) for 4 consecutive years, with -$0.55 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) rose 64.29% to -$0.55 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.68 through Dec 2025, up 38.56% year-over-year, with the annual reading at -$3.68 for FY2025, 38.56% up from the prior year.
  • EPS (Basic) hit -$0.55 in Q4 2025 for Axsome Therapeutics, up from -$0.94 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.26 in Q1 2023 to a low of -$2.13 in Q4 2023.
  • Historically, EPS (Basic) has averaged -$1.22 across 4 years, with a median of -$1.27 in 2023.
  • Biggest five-year swings in EPS (Basic): skyrocketed 75.47% in 2023 and later tumbled 453.85% in 2024.
  • Year by year, EPS (Basic) stood at -$1.43 in 2022, then plummeted by 48.95% to -$2.13 in 2023, then increased by 27.7% to -$1.54 in 2024, then soared by 64.29% to -$0.55 in 2025.
  • Business Quant data shows EPS (Basic) for AXSM at -$0.55 in Q4 2025, -$0.94 in Q3 2025, and -$0.97 in Q2 2025.